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BeBACKGROUND Physicians are not always comfortable deferring treatment of a stenosis in the left anterior descending
(LAD) artery because of the perception that there is a high risk of major adverse cardiac events (MACE). The authors
describe, using the DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation)
trial, MACE rates when LAD lesions are deferred, guided by physiological assessment using fractional ﬂow reserve (FFR)
or the instantaneous wave-free ratio (iFR).
OBJECTIVES The purpose of this study was to establish the safety of deferring treatment in the LAD using FFR or iFR
within the DEFINE-FLAIR trial.
METHODS MACE rates at 1 year were compared between groups (iFR and FFR) in patients whose physiological
assessment led to LAD lesions being deferred. MACE was deﬁned as a composite of cardiovascular death, myocardial
infarction (MI), and unplanned revascularization at 1 year. Patients, and staff performing follow-up, were blinded to
whether the decision was made with FFR or iFR. Outcomes were adjusted for age and sex.
RESULTS A total of 872 patients had lesions deferred in the LAD (421 guided by FFR, 451 guided by iFR). The event rate
with iFR was signiﬁcantly lower than with FFR (2.44% vs. 5.26%; adjusted HR: 0.46; 95% conﬁdence interval [CI]: 0.22
to 0.95; p ¼ 0.04). This was driven by signiﬁcantly lower unplanned revascularization with iFR and numerically lower MI
(unplanned revascularization: 2.22% iFR vs. 4.99% FFR; adjusted HR: 0.44; 95% CI: 0.21 to 0.93; p ¼ 0.03; MI: 0.44%
iFR vs. 2.14% FFR; adjusted HR: 0.23; 95% CI: 0.05 to 1.07; p ¼ 0.06).
CONCLUSIONS iFR-guided deferral appears to be safe for patients with LAD lesions. Patients in whom
iFR-guided deferral was performed had statistically signiﬁcantly lower event rates than those with
FFR-guided deferral. (J Am Coll Cardiol 2019;73:444–53)© 2019 The Authors. Published by Elsevier on behalf
of the American College of Cardiology Foundation. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2018.10.070
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MACE = major adverse cardiac
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FIGURE 1 Flow Chart Outlining Patient Selection
Included in LAD
deferral substudy
(n = 872)
Patients in
DEFINE-FLAIR
with LAD disease
(n = 1,588)
Patients randomized
to iFR-guided
treatment
(n = 794)
Patients randomized
to FFR-guided
treatment
(n = 794)
iFR ≤0.89
Treat
(n = 343)
FFR >0.80
Defer
(n = 421)
FFR ≤0.80
Treat
(n = 373)
iFR >0.89
Defer
(n = 451)
Patients were included from the DEFINE-FLAIR trial. This analysis was focused on patients who had lesions within their LAD, and who then
went on to be deferred on the basis of intracoronary physiology (either iFR or FFR). The total number of patients included in the LAD deferred
analysis was 872. DEFINE-FLAIR ¼ Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation; FFR ¼ fractional ﬂow
reserve; iFR ¼ instantaneous wave-free ratio; LAD ¼ left anterior descending.
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446because the LAD often supplies a large territory of
myocardium (4). It has been suggested that because
of the relatively large area of myocardium at risk,
only hyperemia-based indexes can be trusted for de-
cision making in the LAD (5,6).
In this analysis, we present 1-year major adverse
cardiac events (MACE) rates of patients who have
physiologically-guided deferral of LAD revasculari-
zation in the iFR and FFR arms of the DEFINE-FLAIR
trial.
METHODS
STUDY POPULATION. All patients in the DEFINE-
FLAIR study who had treatment of their LAD steno-
sis deferred, based on an iFR >0.89 or an FFR >0.80,
were included in this study (Figure 1). The inclusion
and exclusion criteria for the DEFINE-FLAIR study
has been described in detail elsewhere (2). To sum-
marize, DEFINE-FLAIR included all patients with
angiographically-determined moderate stenoses.
Notable exclusions included those with left main
disease, prior coronary artery bypass surgery, or
signiﬁcant valve disease.
STUDY PROTOCOL. Cardiac catheterization. Coronary
angiography was performed via the transradial or
transfemoral route at the operator’s discretion.
Before physiological measurements were made,
intracoronary nitrates were administered to control
vasomotor tone. FFR and iFR measurements werethen performed in all appropriate vessels in the
routine manner using a coronary pressure guidewire.
Pre-speciﬁed treatment cutpoints were an FFR of
0.80 and an iFR of 0.89. Revascularization was per-
formed when the physiological value was equal to or
lower than these pre-speciﬁed thresholds, and
revascularization was deferred when it was above
these thresholds.
LAD territory patients are deﬁned as patients un-
dergoing physiological assessment, which included
LAD assessment in which the LAD was deferred based
on the iFR or FFR measurement (Figure 1). Non-LAD
territory patients are deﬁned as patients undergoing
physiological assessment that did not include LAD
assessment in which intervention was deferred in at
least 1 vessel (either Cx or RCA) based on the iFR or
FFR measurement (Figure 1). MACE was deﬁned as
the composite of cardiovascular death, myocardial
infarction, and unplanned revascularization. This
differs slightly from the DEFINE-FLAIR trial, where
MACE was deﬁned as the composite of all-cause
mortality, myocardial infarction, and unplanned
revascularization. Both deﬁnitions of MACE will be
reported in this study.
MI was classiﬁed as either spontaneous or peri-
procedural and as either ST-segment elevation or
non–ST-segment elevation MI. Spontaneous MI was
deﬁned as an event after the ﬁrst 48 h post–
percutaneous coronary intervention (PCI) or 7 days
following coronary artery bypass graft, unrelated to
TABLE 1 Baseline Characteristics of Deferred Patients
LAD Artery Non-LAD Artery
iFR
(n ¼ 451)
FFR
(n ¼ 421)
p
Value
iFR
(n ¼ 343)
FFR
(n ¼ 327)
p
Value
Age, yrs 64.8  11.0 66.1  10.4 0.09 64.9  11.4 65.5  10.5 0.48
Male 340 (75.4) 290 (68.9) 0.03 267 (77.8) 232 (70.9) 0.04
Diabetes 121 (26.8) 117 (27.8) 0.4 97 (28.3) 112 (34.3) 0.21
Hypertension 311 (69.0) 299 (71.0) 0.77 238 (69.4) 241 (73.7) 0.45
Hyperlipidemia 281 (62.3) 268 (63.7) 0.82 223 (65.0) 211 (64.5) 0.46
Acute coronary syndrome 80 (17.7) 75 (17.8) 0.42 70 (20.4) 65 (19.9) 0.87
Previous myocardial infarction 111 (24.6) 97 (23.0) 0.8 108 (31.5) 107 (32.7) 0.94
Previous PCI 142 (31.5) 143 (34.0) 0.42 162 (47.2) 157 (48.0) 0.8
Values are mean  SD or n (%).
FFR ¼ fractional ﬂow reserve; iFR ¼ instantaneous wave-free ratio; LAD ¼ left anterior descending;
PCI ¼ percutaneous coronary intervention.
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447the procedure. MI was deﬁned by a typical rise and
gradual fall (troponin) or more rapid rise and fall
(creatine kinase-MB) of biochemical markers of
myocardial necrosis with at least 1 of the following:
ischemic symptoms; development of new patholog-
ical Q waves on the ECG; and/or ECG changes indic-
ative of ischemia. Periprocedural MI was considered
an event within the ﬁrst 48 h after PCI and within
7 days following coronary artery bypass graft.
Revascularization was considered to be unplanned
when it was not the index procedure and was not
identiﬁed at the time of the index procedure as a
staged procedure to occur within 60 days. Addition-
ally, unplanned revascularization required symptoms
consistent with ischemia. All events were indepen-
dently adjudicated.
STATISTICAL ANALYSIS. The objective of this study
was to compare event rates between physiology
techniques (iFR vs. FFR) in patients for whom
revascularization was deferred, separately in LAD
territory patients and non-LAD territory patients.
Baseline and procedural characteristics of patients
were analyzed in the following manner. Categorical
and binary variables were compared between groups
using chi-square tests. Continuous variables were
compared using Student’s t-test, or Wilcoxon signed-
rank test in case of non-normal distributions.
For MACE and its components, a time-to-event
analysis was performed by Cox survival modeling.
Participants who withdrew from the study before
reaching 1 year of follow-up and who were event-free
at their last visit were censored at their time of last
visit. Testing of validity of proportional hazard
assumption was done using Schoenfeld residuals.
There were no signs of violations of proportional
hazards assumption.
Results are reported using hazard ratios (HRs), 95%
2-sided conﬁdence intervals (CIs) and cumulative
hazard curves. Analyses were performed in an unad-
justed manner. In addition, adjustment for age and
sex was performed. Indeed, despite randomization
at the trial level, sex was found to be imbalanced
between iFR and FFR groups in this study of deferred
patients. Moreover, iFR patients were slightly
younger than FFR patients, although this difference
did not reach statistical signiﬁcance. Results are
presented as adjusted for age and sex in text, and
both as unadjusted and adjusted in the tables.
RESULTS
LAD ARTERY. The baseline characteristics of patients
who had revascularization deferred in their LAD areshown in Table 1. Patients in the iFR group were
more likely to be male (75.4% iFR vs. 68.9% FFR;
p ¼ 0.03). There were no other statistical differences
in baseline characteristics between the iFR and FFR
arms in patients with LAD territory disease who had
revascularization deferred on the basis of intra-
coronary physiology. The majority of patients were
classiﬁed with stable disease. A total of 80 patients
(17.7%) in the iFR group and 75 patients (17.8%) in
the FFR group had an acute coronary syndrome.
There was no signiﬁcant difference between iFR and
FFR groups in proportions of patients taking aspirin
(p ¼ 0.65), statins (p ¼ 0.78), beta-blockers
(p ¼ 0.39), angiotensin-converting enzyme
inhibitors (p ¼ 0.21), angiotensin receptor blockers
(p ¼ 0.40), and calcium channel antagonists
(p ¼ 0.66). There were no signiﬁcant differences in
medical therapy at 30 days and 1 year. For treated
patients, all were treated with drug-eluting stents.
A total of 1,588 patients in DEFINE-FLAIR had
physiological assessment in the LAD territory in total
(794 patients in each arm). The proportion of patients
with >1 evaluated stenosis was similar between iFR
and FFR at 31.0% (n = 1,106) and 32.9% (n = 1,129),
respectively (p ¼ 0.42). The mean iFR value was 0.89
 0.09, and the mean FFR value 0.82  0.09 in the
LAD territory. When using iFR or FFR to guide
revascularization in the LAD territory, the 1-year
MACE rate was 4.03% for iFR and 5.54% for FFR in all
patients, both treated and deferred (adjusted HR:
0.66; 95% CI: 0.40 to 1.08; p ¼ 0.1).
The proportion of patients with 0, 1, or
>1 hemodynamically signiﬁcant stenosis was 55.3%,
42.2%, and 2.5% in iFR, and 51.3%, 41.4%, and 7.2% in
FFR (p < 0.01). There were 376 hemodynamically
signiﬁcant stenoses in the iFR arm and 452 in the FFR
TABLE 2 Procedural Characteristics of Deferred Patients
LAD Artery Non-LAD Artery
iFR
(n ¼ 451)
FFR
(n ¼ 421)
p
Value
iFR
(n ¼ 343)
FFR
(n ¼ 327)
p
Value
Radial access 327 (72.5) 308 (73.2) 0.97 246 (71.7) 238 (72.8) 0.76
Total number of
evaluated lesions
634 574 — 378 357 0.76
Mean iFR/FFR value 0.94  0.03 0.87  0.04 — 0.97  0.03 0.91  0.05 —
Values are n (%), n, or mean  SD.
Abbreviations as in Table 1.
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448arm. Stent length and diameter was equivalent
between iFR and FFR groups. The procedural char-
acteristics for patients in whom revascularization in
the LAD was deferred on the basis of physiology is
summarized in Table 2.
The mean iFR was 0.94  0.03 versus mean FFR
value 0.87  0.04 in deferred stenoses. Among the
872 patients with deferred LAD lesions, there was no
difference in lesion location. A total of 40% ofFIGURE 2 Summary of Clinical Events in LAD-Deferred Patients
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Sen, S. et al. J Am Coll Cardiol. 2019;73(4):444–53.
This ﬁgure outlines the primary endpoint in patients with left anterior descending stenoses who were deferred according intracoronary physiology. Major
adverse cardiac events were deﬁned as the composite of cardiovascular death, myocardial infarction, and unplanned revascularization. The solid blue line
denotes the fractional ﬂow reserve arm, and the dashed orange line denotes the instantaneous wave-free ratio arm. Instantaneous wave-free ratio–guided
deferral was associated with a signiﬁcantly lower major adverse cardiac events rate (adjusted hazard ratio: 0.46; 95% conﬁdence interval: 0.22 to 0.95;
p ¼ 0.04).
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4499 patients after FFR-guided deferral (0.44% iFR vs.
2.14% FFR; adjusted HR: 0.23; 95% CI: 0.05 to 1.07;
p ¼ 0.06) (Table 3, Figure 2). Target vessel MI occurred
in 1 patient in iFR compared with 6 patients with FFR
(0.22% vs. 1.43%; adjusted HR: 0.15; 95% CI: 0.02 to
1.23; p ¼ 0.08) (Figure 2).
NON-LAD TERRITORY. The baseline characteristics
of patients who had revascularization deferred in the
non-LAD territories are shown in Table 1. Patients in
the iFR group were more likely to be male (77.8% iFR
vs. 70.9% FFR; p ¼ 0.04). There were no other
statistical differences in baseline characteristics be-
tween the iFR and FFR arms in patients with non-LAD
territory disease who had revascularization deferredon the basis of intracoronary physiology (Table 1).
The majority of patients were classiﬁed with stable
disease. A total of 70 patients (20.4%) in the iFR
group and 65 patients (19.9%) in the FFR group had
an acute coronary syndrome.
A total of 834 patients had physiological assess-
ment in the non-LAD territory (409 iFR, 425 FFR).
There were 457 stenosis in the iFR arm and 470
stenoses in the FFR arm. The proportion of patients
with >1 evaluated vessel was similar between iFR and
FFR, at 11.2% and 9.4%, respectively (p ¼ 0.38). The
mean iFR value was 0.95  0.10 and the mean FFR
value 0.87  0.10 in the non-LAD territory. The event
rate in the overall population (both treated and
TABLE 3 Clinical Outcomes in LAD-Deferred Patients
Unadjusted Adjusted
iFR Group
(n ¼ 451)
FFR Group
(n ¼ 421)
Hazard Ratio
(95% CI)
p
Value
Hazard Ratio
(95% CI)
p
Value
MACE (cardiovascular death, MI, unplanned revascularization) 11 (2.44) 23 (5.46) 0.47 (0.23–0.96) 0.04* 0.46 (0.22–0.95) 0.04*
Cardiovascular death 0 (0.00) 1 (0.24)
MACE (all-cause death, MI, unplanned revascularization) 15 (3.33) 27 (6.41) 0.54 (0.29–1.02) 0.06 0.53 (0.28–1.01) 0.05
All-cause death 4 (0.89) 5 (1.19) 0.76 (0.21–2.84) 0.69 0.77 (0.21–2.86) 0.69
MI 2 (0.44) 9 (2.14) 0.24 (0.05–1.11) 0.07 0.23 (0.05–1.07) 0.06
Target vessel MI 1 (0.22) 6 (1.43) 0.16 (0.02–1.30) 0.09 0.15 (0.02–1.23) 0.08
Nontarget vessel MI 0 (0.00) 2 (0.48)
Periprocedural MI 1 (0.22) 1 (0.24) 1.00 (1.00–1.00) 1.00 1.00 (1.00–1.00) 1.00
Unplanned revascularization 10 (2.22) 21 (4.99) 0.45 (0.21–0.95) 0.04* 0.44 (0.21–0.93) 0.03*
TVR 7 (1.55) 15 (3.56) 0.44 (0.18–1.07) 0.07 0.42 (0.17–1.04) 0.06
Non-TVR 3 (0.67) 6 (1.43) 0.47 (0.12–1.88) 0.29 0.47 (0.12–1.88) 0.28
Values are n (%) unless otherwise indicated. *Statistically signiﬁcant p values.
CI ¼ conﬁdence interval; MACE ¼ major adverse cardiac events; MI ¼ myocardial infarction; TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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450deferred) with non-LAD disease was 7.58% with iFR
and 6.35% with FFR (HR: 1.27; 95% CI: 0.73 to 2.21;
p ¼ 0.4).
The proportion of patients with 0, 1, or
>1 hemodynamically signiﬁcant stenosis was 83.9%,
15.2%, and 1.0% in iFR, and 76.9%, 21.9%, and 1.2% in
FFR (p ¼ 0.04). The number of signiﬁcant stenoses
was signiﬁcantly lower in the iFR arm (70 vs. 104;
p ¼ 0.01). Stent length and diameter was equivalent
between iFR and FFR groups; however, more stents
were placed in the FFR arm. The procedural charac-
teristics for patients in whom revascularization in the
non-LAD territories was deferred on the basis of
physiology is summarized in Table 2.
The mean iFR was 0.97  0.03 versus mean FFR
value 0.91  0.05 in deferred stenoses. iFR-based
deferral of non-LAD stenoses was associated with a
MACE rate of 5.25% at 1 year compared with a MACE
rate of 5.20% with FFR (adjusted HR: 1.18; 95% CI:
0.59 to 2.38; p ¼ 0.63) (Figure 3).
Unplanned revascularization occurred in 15 pa-
tients in the iFR-deferred group and 16 patients in the
FFR-deferred group (4.37% iFR vs. 4.89% FFR;
adjusted HR: 0.98; 95% CI: 0.47 to 2.04; p ¼ 0.97)
(Table 4). The target vessel was revascularized in
5 patients of the iFR group compared with 10 patients
of the FFR group (1.46% iFR vs. 3.06% FFR; adjusted
HR: 0.52; 95% CI: 0.17 to 1.55; p ¼ 0.24).
Myocardial infarction occurred in 5 patients after
iFR-guided non-LAD deferral at 1 year compared with
6 patients after FFR-guided deferral (1.46% iFR vs.
1.83% FFR; adjusted HR: 1.09; 95% CI: 0.29 to 4.08;
p ¼ 0.89) (Table 4). Target vessel MI occurred in
2 patients in iFR and 2 patients with FFR (0.58% vs.
0.61%; adjusted HR: 0.87; 95% CI: 0.12 to 6.15;
p ¼ 0.88).DISCUSSION
Physiologically-guided deferral of revascularization
in the LAD is not associated with an unacceptably
high MACE rate. The outcomes of patients having this
deferral guided by iFR rather than by FFR are no
worse, and may be better.
DEFERRAL OF INTERVENTION BASED ON FFR. The
principle of physiological guidance of revasculariza-
tion is to identify lesions in which deferral is likely to
be safe (7). Among angiographically moderate lesions,
FFR has been shown to successfully identify lesions
that can safely be managed conservatively (8). This
manifests as a reduction in unplanned revasculari-
zation and MI with FFR-guided revascularization
when compared with angiography-guided revascu-
larization. This ability to reduce MI and unplanned
revascularization led to a paradigm shift away from
angiography-guided intervention to FFR-guided
intervention and was pivotal in the adoption of FFR
into guidelines (9,10).
The ability of FFR to discern the risk of stenoses
has not been compared with other indexes in a
randomized and prospective fashion until DEFINE-
FLAIR. Furthermore, DEFINE-FLAIR was the ﬁrst
study to include a predominance of stenoses most
commonly represented in clinical practice. When
FFR has been previously studied in this distribution
of patients, there has been some concern as to its
safety and, therefore, utility in guiding revasculari-
zation (11).
Within DEFINE-FLAIR, in non-LAD lesions, FFR-
guided deferral had similar outcomes to iFR-guided
deferral. For LAD lesions, there was a trend toward
better outcomes in those with iFR-guided deferral
than those with FFR-guided deferral. The difference
FIGURE 3 Kaplan-Meier for MACE in Non-LAD Patients
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Months Since Randomization
HR: 1.22; 95% CI: 0.60-2.44; p = 0.58
Number at risk
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343 321 314 312 312 312 305 295 291 288 285 280 225iFR
6 7 8 9 10 11 12
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Primary endpoint in patients with non-LAD stenoses who were deferred according to intracoronary physiology. MACE was deﬁned as the
composite of cardiovascular death, myocardial infarction, and unplanned revascularization. The solid blue line denotes the FFR arm, and the
dashed orange line denotes the iFR arm. There was no difference in the MACE rate between iFR- and FFR-guided deferral (adjusted hazard
ratio: 1.18; 95% conﬁdence interval: 0.59 to 2.38; p ¼ 0.63). Abbreviations as in Figure 1.
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451in the composite endpoint was driven by statistically
higher unplanned revascularization and numerically
higher myocardial infarction in the LAD in the FFR
arm.
POTENTIAL CHALLENGES FOR HYPEREMIA-DEPENDENT
INDEXES IN THE LAD. When ﬂow measurements are
available, previous work has indicated that coronaryTABLE 4 Clinical Outcomes in Non–LAD-Deferred Patients
iFR Group
(n ¼ 343)
MACE (cardiovascular death, MI, unplanned revascularization) 18 (5.25)
Cardiovascular death 3 (0.87)
MACE (all-cause death, MI, unplanned revascularization) 20 (5.83)
All-cause death 5 (1.46)
MI 5 (1.46)
Target vessel MI 2 (0.58)
Non-target vessel MI 3 (0.87)
Periprocedural MI 0 (0.00)
Unplanned revascularization 15 (4.37)
TVR 5 (1.46)
Non-TVR 10 (2.92)
Values are n (%) unless otherwise indicated.ﬂow reserve (CFR), the extent of hyperemic ﬂow
during adenosine administration, is the most power-
ful predictor of events (12–14). Patients with impaired
CFR have a worse prognosis. Recent studies have
demonstrated that patients with abnormal CFR but
normal FFR are prone to higher adverse event rates
(15). The discordance of CFR to FFR can be as high asUnadjusted Adjusted
FFR Group
(n ¼ 327)
Hazard Ratio
(95% CI)
p
Value
Hazard Ratio
(95% CI)
p
Value
17 (5.20) 1.22 (0.60–2.44) 0.58 1.18 (0.59–2.38) 0.63
0 (0.00)
21 (6.42) 1.05 (0.56–1.99) 0.88 1.04 (0.55–1.97) 0.9
4 (1.22) 1.20 (0.32–4.48) 0.78 1.28 (0.34–4.76) 0.72
6 (1.83) 1.20 (0.32–4.45) 0.79 1.09 (0.29–4.08) 0.89
2 (0.61) 0.96 (0.14–6.83) 0.97 0.87 (0.12–6.15) 0.88
2 (0.61) 1.43 (0.24–8.54) 0.7 1.32 (0.22–7.92) 0.76
2 (0.61)
16 (4.89) 1.02 (0.49–2.10) 0.97 0.98 (0.47–2.04) 0.97
10 (3.06) 0.53 (0.18–1.57) 0.25 0.52 (0.17–1.55) 0.24
6 (1.83) 1.90 (0.65–5.55) 0.24 1.80 (0.62–5.29) 0.28
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Deferral of LAD revascu-
larization based on assessment of coronary physiology
by iFR was associated with lower adverse cardiac
event rates than when decisions were guided by
measurement of FFR.
TRANSLATIONAL OUTLOOK: Future studies
should compare available methods of evaluating the
physiological impact of stenotic coronary artery le-
sions on clinical outcomes in patients with other
anatomical patterns of disease.
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that a proportion of patients in the FFR arm of this
study had abnormal CFR values, and this predisposed
them to higher event rates in the FFR arm.
The same could also apply to iFR; however, the
agreement between iFR and CFR has been demon-
strated to be signiﬁcantly closer than that of FFR and
CFR (17). Therefore, the proportion of patients
in whom iFR is normal and CFR abnormal is lower,
possibly explaining the lower event rate in the
iFR-deferred patients (15).
iFR-BASED DEFERRAL. Physicians are correct to
question the safety of any technique proposed as an
alternative to one that is accepted as safe. The LAD
has been highlighted as a territory in which reliance
on nonhyperemic indexes may be particularly
dangerous (5,6). This is because the LAD supplies a
large amount of myocardium, and any index of ste-
nosis severity will need to also reﬂect the amount of
myocardium subtended by the vessel. It has been
assumed that the amount of myocardium can only be
appreciated during hyperemia.
This analysis suggests that, for patients having
LAD lesions deferred based on physiology, the event
rate is not higher than that of patients in which
non-LAD lesions are deferred. Furthermore, there is
no sign of increased risk if guided by iFR compared
with those guided by FFR. This suggests that hyper-
emia is not required to safely defer lesions in the left
anterior descending artery.
STUDY LIMITATIONS. This is a post hoc analysis of
DEFINE-FLAIR regarding the safety of deferral of
PCI using nonhyperemic physiology, particularly in
the LAD (5,6). This is not itself a randomized
controlled trial. However, it beneﬁts from the
blinding provided by the DEFINE FLAIR trial, which
ensures that the patients and their clinical care staff
were unaware of allocation arm so that decisions to
revascularize were unbiased. Additionally, the
endpoint adjudication committee was blinded to
allocation arm.
Our ﬁndings should be considered hypothesis-
generating, and further research in the ﬁeld is
necessary. Nevertheless, our results conﬁrm there isno safety hazard for using iFR to defer lesions in the
LAD. There were only 872 patients with LAD deferral.
However, this is not unsatisfactory by comparison to
the dataset upon which the safety of FFR deferral was
established, because it is greater than the total num-
ber of patients undergoing physiological deferral in
DEFER (Fractional Flow Reserve to Determine the
Appropriateness of Angioplasty in Moderate Coronary
Stenosis) (n ¼ 91 patients) and FAME (Fractional Flow
Reserve versus Angiography for Guiding Percuta-
neous Coronary Intervention) (n #509 patients).
CONCLUSIONS
iFR-guided deferral appears to be safe for patients
with LAD lesions. Patients in whom iFR-guided
deferral was performed had statistically signiﬁcantly
lower event rates than those with FFR-guided
deferral. Further studies would be useful to explore
these ﬁndings in more detail.
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